Benefits
Antibacterial and antiviral activity in laboratory tests
In the laboratory, monolaurin, alone or with preservatives, at 1 percent strength cut the infectivity of fourteen enveloped human viruses by more than 99.9 percent within an hour, and it inhibited streptococci and Staphylococcus aureus while blocking their toxin production. E. coli and Salmonella growth was unaffected. These are direct-contact concentrations, and nobody has shown they are reached in the body after swallowing it.
Oral immune support has not been tested in human trials
A literature review of monolaurin as a dietary supplement found only three peer-reviewed human studies showing antimicrobial effects in the body, and all three applied it topically, inside the vagina or mouth. It found no peer-reviewed evidence for clinical use as an oral supplement. A later placebo-controlled trial of a monolaurin vaginal gel for bacterial vaginosis found it no more effective than placebo.
Infection resistance seen only in small mouse studies
In rodent experiments, mice infected with Staphylococcus aureus and dosed by mouth with monolaurin, vancomycin or both had 50 to 70 percent survival, while groups fed coconut oil fared about as badly as untreated controls. Groups held ten to twelve mice, the work came from one research group, and no comparable test exists in people.
Immunomodulatory effects on T cells lean toward suppression
Supplement marketing frames monolaurin as immune support, but in human T cells studied in the laboratory it pushed the other way: it disturbed the cell membrane, blunted activation signaling and reduced output of interleukin-2, interferon-gamma, TNF-alpha and IL-10. Whether anything similar happens after oral use is unknown, because this was cell work.
Gut bacteria changes in mice, not all of them favorable
In one mouse study, glycerol monolaurate added to a low-fat diet at relatively low doses increased body fat, shifted the gut microbiota, lowered Akkermansia muciniphila and raised blood inflammatory markers, and the authors called for its use to be reassessed. A later study from the same laboratory reported friendlier shifts and no rise in inflammation, and no human study has looked.
Mechanism of action
Disrupting lipid membranes and viral envelopes
Monolaurin is an amphiphilic monoglyceride, part fat and part water-soluble, that inserts into lipid membranes. In laboratory tests it inactivated enveloped RNA and DNA viruses by disintegrating the viral envelope. Viruses without a lipid envelope offer no such target.
Blocking bacterial toxin production
At concentrations below those needed to stop growth, glycerol monolaurate reduced production of toxic shock syndrome toxin 1, hemolysins and other exotoxins by Staphylococcus aureus and streptococci. Bacteria that produce lipase could overcome its growth inhibition, a reminder that fat-splitting enzymes can inactivate it.
Altering T cell membrane signaling
In primary human T cells, GML changed the order of the plasma membrane and reduced the clustering of signaling proteins such as LAT, PLC-gamma and AKT after receptor stimulation. Calcium influx and cytokine release fell. This is a dampening effect on immune cell activation, observed in culture.
Digestion and what reaches the blood
Monoglycerides are a normal product of fat digestion, and gut lipases can split monolaurin into lauric acid and glycerol before absorption. Monolaurin is measurable in human serum, but published data do not show how much of an oral dose survives digestion or what blood level a supplement produces.
Clinical trials
Narrative review of PubMed and commercial sources on the clinical use, dosage, bioavailability, efficacy and safety of monolaurin as a dietary supplement (Barker LA, Bakkum BW, Chapman C 2019, J Chiropr Med 18(4):305-310, PMID 32952476).
Twenty-eight published articles judged relevant to the clinical use of monolaurin.
Many articles described antimicrobial effects in vitro, but only three peer-reviewed papers showed antimicrobial effects inside the human body, and all three involved intravaginal or intraoral, that is topical, use. The reviewers found no peer-reviewed evidence for clinical use of monolaurin as a human dietary supplement other than as a nutrient.
Prospective observational cohort study using targeted serum metabolomics with six months of follow-up (Sola D, Tonello S, Casciaro GF, et al. 2025, Int J Mol Sci 26(6):2452, PMID 40141096).
Healthcare workers at a university hospital in Novara, Italy: 2,712 enrolled, with an analysed cohort of 1,000, mean age 46.4, mostly women.
Higher serum monolaurin was associated with a lower risk of SARS-CoV-2 infection at 3 and 6 months, with a proposed protective cut-off of 0.45 micrograms per mL. Infections were few (21 by 3 months, 26 by 6 months) and monolaurin predicted them weakly (area under the curve 0.57 and 0.62). The authors suggested a supplement role, but no one was given monolaurin, so the design cannot show that supplements raise serum levels or lower infection risk.
Multicenter, double-blind, randomized placebo-controlled trial of a topical gel applied twice daily for 3 days, not an oral supplement (Mancuso AC, Widdice LE, Hughes BL, Schlievert P, Swamy GK, Stockdale CK, Bernstein DI, Winokur PL 2020, J Low Genit Tract Dis 24(3):277-283, PMID 32379102).
109 nonpregnant, non-breastfeeding women aged 18 to 50 with confirmed bacterial vaginosis, 73 randomized to monolaurin gel and 36 to placebo gel.
Clinical cure was 17 percent with monolaurin and 25 percent with placebo (p = .42), and the authors concluded monolaurin was no more clinically or microbiologically effective than placebo. Lactobacillus counts rose in the monolaurin group. The gel was applied directly where the bacteria live, a far easier test than an oral capsule, and it still did not beat placebo.
Rodent in vitro and in vivo study; animal evidence only (Manohar V, Echard B, Perricone N, Ingram C, Enig M, Bagchi D, Preuss HG 2013, J Med Food 16(6):499-503, PMID 23767861).
Female C3H mice, 10 to 12 per group, given coconut oils by mouth for a week before Staphylococcus aureus challenge and for 30 days after, compared with groups given monolaurin, vancomycin or both.
Groups receiving vancomycin, monolaurin or the combination had 50 to 70 percent survival, while the coconut oil groups were close to controls at 0 to 16 percent. The coconut oils also lacked bactericidal activity in vitro. The result argues that eating coconut oil is not a stand-in for monolaurin, but it remains a small animal study that has not been repeated in people.